Anti-vascular endothelial growth factor agents for pediatric retinal diseases

International Ophthalmology Clinics

Volumn 51, Issue 1, 2011, Pages 185-199

  Wykoff, Charles C ^a   Houston, Samuel K ^a   Berrocal, Audina M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BEVACIZUMAB; PEGAPTANIB; STEROID; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ABLATION THERAPY; ARTICLE; BLEEDING; BLINDNESS; CHOROID DISEASE; CHOROIDAL NEOVASCULAR MEMBRANE; CRYOTHERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EXUDATIVE RETINITIS; EYE DISEASE; FAMILIAL EXUDATIVE VITREORETINOPATHY; HUMAN; IRIS DISEASE; IRIS NEOVASCULARIZATION; LASER COAGULATION; PEDIATRICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA BLOOD VESSEL; RETINA DETACHMENT; RETINA DEVELOPMENT; RETINA DISEASE; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINAL TELANGIECTASIA; RETROLENTAL FIBROPLASIA; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VITRECTOMY; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHILD; HUMANS; RETINAL DISEASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650852493     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e318200df83     Document Type: Article

References (84)

1. Goldberg MF. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. Am J Ophthalmol. 1997;124:587-626.
2. Ashton N, Cook C. Direct observation of the effect of oxygen on developing vessels: preliminary report. Br J Ophthalmol. 1954;38:433-440.
3. Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954; 38:397-432.
4. Michaelson IC. Vascular morphogenesis in the retina of the cat. J Anat. 1948;82: 167-174.
5. Roth AM. Retinal vascular development in premature infants. Am J Ophthalmol. 1977; 84:636-640.
6. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci. 2000;41: 1217-1228.
7. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584.
8. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
9. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
10. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6: 389-395.
11. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol. 2002;39:225-237.
12. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. 1997;12:99-109.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
14. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1432-1444.
16. Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247:1-11.
17. Arevalo JF, Garcia-Amaris RA. Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev. 2009;5:39-46.
18. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46:726-733.
19. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
20. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50:4807-4813.
21. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
22. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113: 1695e1-1695e15.
23. Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore. 2008;37: 591-593.
24. Scartozzi R, Chao JR, Walsh AC, et al. Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. Eye (Lond). 2009;23:1229.
25. Al-Dhibi H, Khan AO. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS. 2009;13: 400-402.
26. Avery RL. Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern. J AAPOS. 2009;13:329-331.
27. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helixloop- helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510-5514.
28. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399:271-275.
29. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
30. Hellstrom A, Carlsson B, Niklasson A, et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab. 2002;87:3413-3416.
31. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98:5804-5808.
32. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;14(suppl A):S140-S144.
33. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177-5182.
34. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-1028.
35. Anand A, Madhavan H, Neelam V, et al. Use of polymerase chain reaction in the diagnosis of fungal endophthalmitis. Ophthalmology. 2001;108:326-330. (Pubitemid 32115964)
36. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133-140.
37. Gilbert C, Rahi J, Eckstein M, et al. Retinopathy of prematurity in middle-income countries. Lancet. 1997;350:12-14.
38. Steinkuller PG, Du L, Gilbert C, et al. Childhood blindness. J AAPOS. 1999;3:26-32.
39. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Arch Ophthalmol. 1990;108:195-204.
40. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003; 121:1684-1694.
41. Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000;156:1337-1344.
42. Sonmez K, Drenser KA, Capone A Jr, et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology. 2008;115:1065el-1070e1.
43. Nonobe NI, Kachi S, Kondo M, et al. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina. 2009;29:579-585.
44. Sato T, Kusaka S, Shimojo H, et al. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:1599-1603.
45. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831-838.
46. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450-1455.
47. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina. 2008;28(3 suppl):S13-S18.
48. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol. 2009;148: 536e2-543e2.
49. Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevacizumab as antivascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008;126:1161-1163.
50. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38: 233-237.
51. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina. 2008;28(3 suppl):S19-S25.
52. Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246:1061-1063.
53. Quiram PA, Drenser KA, Lai MM, et al. Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen). Retina. 2008;28 (3 suppl):S8-S12.
54. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS One. 2008;3:e3554.
55. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol. 1999;155:421-428.
56. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci. 1999;19: 5731-5740.
57. Schwarz Q, Gu C, Fujisawa H, et al. Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve. Genes Dev. 2004;18:2822-2834.
58. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53-67.
59. Harris GS. Coats' disease, diagnosis and treatment. Can J Ophthalmol. 1970;5: 311-320.
60. Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol. 2007;245:1387-1388.
61. Quiroz-Mercado H, Ustariz-Gonzalez O, Martinez-Castellanos MA, et al. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol. 2007;22:109-125.
62. Venkatesh P, Mandal S, Garg S. Management of Coats disease with bevacizumab in 2 patients. Can J Ophthalmol. 2008;43:245-246.
63. Alvarez-Rivera LG, Abraham-Marin ML, Flores-Orta HJ, et al. [Coat's disease treated with bevacizumab (Avastin)]. Arch Soc Esp Oftalmol. 2008;83:329-331.
64. Cackett P, Wong D, Cheung CM. Combined intravitreal bevacizumab and argon laser treatment for Coats' disease. Acta Ophthalmol. 2010;88:e48-e49.
65. Cakir M, Cekic O, Yilmaz OF. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS. 2008;12:309-311.
66. Criswick VG, Schepens CL. Familial exudative vitreoretinopathy. Am J Ophthalmol. 1969;68:578-594.
67. Canny CL, Oliver GL. Fluorescein angiographic findings in familial exudative vitreoretinopathy. Arch Ophthalmol. 1976;94:1114-1120.
68. Van Nouhuys CE. Juvenile retinal detachment as a complication of familial exudative vitreoretinopathy. Fortschr Ophthalmol. 1989;86:221-223.
69. Warden SM, Andreoli CM, Mukai S. The Wnt signaling pathway in familial exudative vitreoretinopathy and Norrie disease. Semin Ophthalmol. 2007;22:211-217.
70. Zhao S, Overbeek PA. Elevated TGFbeta signaling inhibits ocular vascular development. Dev Biol. 2001;237:45-53.
71. Parmalee NL, Kitajewski J. Wnt signaling in angiogenesis. Curr Drug Targets. 2008;9: 558-564.
72. Tagami M, Kusuhara S, Honda S, et al. Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246: 1787-1789.
73. Lin KL, Hirose T, Kroll AJ, et al. Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition. Semin Ophthalmol. 2009;24: 70-76.
74. Rich R, Vanderveldt S, Berrocal AM, et al. Treatment of choroidal neovascularization associated with Best's disease in children. J Pediatr Ophthalmol Strabismus. 2009;46: 306-311.
75. Cakir M, Cekic O, Yilmaz OF. Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease. J AAPOS. 2009;13: 94-96.
76. Sundaram N, Uparkar M, Athale A, et al. Intravitreal bevacizumab (Avastin) in a pediatric case of pathologic myopia. Retinal Cases Brief Rep. 2007;1:192-194.
77. Cakir M, Cekic O, Yilmaz OF. Intravitreal bevacizumab for idiopathic choroidal neovascularization. J AAPOS. 2009;13:296-298.
78. Lee SY, Kim DK, Cho JH, et al. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol. 2008;126:953-958.
79. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf. 2006;5:553-566.
80. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
81. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113: 2002e1-2012el.
82. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86:372-376.
83. Wong LJ, Desai RU, Jain A, et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina. 2008;28:1151-1158.
84. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol. 2009;54:372-400.